Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Apollo to Acquire Minority Stake in Syntegon from CVC | Contract Pharma
Live From

Interphex

April 21, 2026 - April 23, 2026
|
New York, NY
Sponsored By
Interphex

Apollo to Acquire Minority Stake in Syntegon from CVC

Apollo to support new momentum and local expertise for the North American market.

By: Contract Pharma Staff

CVC Capital Partners (CVC) announced that an investor group led by Apollo-managed funds is acquiring a 37% minority stake in Syntegon from CVC. Based on Syntegon’s development, CVC is reaffirming its commitment and maintaining its majority shareholding with the remaining 63% of shares.

This transaction marks the starting point for Syntegon’s next phase of growth. The team at Apollo shares the strategic vision of CVC and Syntegon and strengthens the partnership with new momentum and local expertise for the North American market.

Torsten Türling, CEO of Syntegon, said, “This transaction marks a milestone for Syntegon. CVC remains the ideal partner for us and we are pleased to continue our successful collaboration. At the same time, we are gaining valuable new momentum with Apollo. Our current position is the result of an outstanding performance of our global team. In recent years, we have expanded our product portfolio with outstanding innovations while improving our operational excellence. Today, we are the leading strategic partner for our customers and serve the industry’s largest installed base of approximately 72,000 technically highly complex systems.”

Focus on Expansion in the North American Market

In the next growth phase, Syntegon aims to gain further share in mission-critical and largely non-cyclical growing end markets. A focus is on the expansion in the U.S., where Apollo’s aims to provide new momentum.

Under the existing management, Syntegon continues to operate from its headquarters in Stuttgart and will build on its growth trajectory.

The transaction is subject to customary regulatory approvals. The parties have agreed to maintain confidentiality regarding the financial details of the agreement.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters